Back HIV Prevention

No New HIV Infections Among Kaiser PrEP Users, But Cascade Shows Missed Opportunities

No new HIV infections have occurred among nearly 5000 people who started Truvada for pre-exposure prophylaxis (PrEP) in the Kaiser Permanente Northern California health system, according to a letter in the July 29 edition of Clinical Infectious Diseases.

alt

Read more:

IAS 2017: Experts Agree that Intermittent Oral PrEP Probably Won't Work for Women

Two presenters at the recent International AIDS Society Conference on HIV Science (IAS 2017) in Paris told delegates that both trial results and analysis of drug levels support the idea that event-related or "on demand" pre-exposure prophylaxis (PrEP) might not be sufficiently powerful to prevent HIV infection in women and trans men via vaginal sex.

alt

Read more:

IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says

HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IAS 2017: Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV

Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir (Tivicay) was associated with lipid reductions in people with HIV at higher risk of heart disease, according to results of the NEAT 022 study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

IAS 2017: People with HIV Are at Risk for Liver Fibrosis and Steatosis

Metabolic syndrome, type 2 diabetes, and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do not have viral hepatitis coinfection, according to research presentedat the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.alt

Read more:

IAS 2017: Who Are Trans Women Acquiring HIV From?

There is a lot we don't know about trans women's HIV risk, why they are so vulnerable to HIV, and who trans women are acquiring HIV from. A study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) attempted to answer these questions, but in the process uncovered another mystery: is there a hidden population of heterosexual men who have sex with trans women and who are themselves at high risk of acquiring and transmitting HIV? One thing the study did make clear, however, is that a lot of HIV infections among trans women may be due to injecting drugs rather than sex.

alt

Read more:

IAS 2017: Medical Male Circumcision for HIV Prevention Has Benefits for Women Too

South African women whose most recent sexual partner was circumcised are less likely to have HIV, suggesting that voluntary medical male circumcision programs have benefits for women, too, according to a study presented to the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

CDC Continues to Recommend Annual HIV Testing for Gay Men

The U.S. Centers for Disease Control and Prevention (CDC) recently reaffirmed its recommendation that sexually active gay and bisexual men should undergo at least annual HIV screening, according to a report in the August 11 edition of the CDC's Morbidity and Mortality Weekly Report. However, some local providers advise more frequent HIV and sexually transmitted infection tests.

alt

Read more:

IAS 2017: VRC01 Antibody Can Delay But Not Prevent HIV Rebound

A broadly neutralizing antibody modestly delayed the resurgence of viral replication following interruption of antiviral therapy (ART) started during very early infection, but all study participants ultimately experienced viral rebound, according to results presented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

San Francisco Annual Report Shows Continued Drop in HIV Infections

The San Francisco Department of Public Health has released its HIV Epidemiology Annual Report for 2016, showing that the number of new infections continues to decline, with decreases seen across demographic groups. Homeless people, however, have higher rates of infection and poorer treatment outcomes.

alt

Read more:

IAS 2017: Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP

A single oral dose of MK-8591, a long-acting antiretroviral in a novel drug class, suppressed HIV for 7 days in an early clinical trial, and the drug also appears to protect monkeys from rectal infection with an HIV-like virus, researchers reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IAS 2017: Doravirine Combo Pill Looks Good for Initial HIV Treatment

A single-tablet regimen containing the next-generation NNRTI doravirine reduced HIV viral load as much as an efavirenz-based coformulation, but it had a more favorable side effect profile, according to results from the DRIVE-AHEAD studypresented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IAS 2017: Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa

One of the first studies to explore the acceptability, safety, and use of pre-exposure prophylaxis (PrEP) in adolescents in an African context has found that PrEP was safe and tolerable, although PrEP usage and adherence did tail off during the 12 months of the program.

alt

Read more:

IAS 2017: Boosted Darunavir Plus Lamivudine Matches 3-Drug Regimen

A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results from the ANDES study, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

IAS 2017: First Protease Inhibitor Combo Pill Maintains Viral Suppression

The first once-daily single-tablet regimen containing a protease inhibitor maintained viral suppression in almost everyone who switched after achieving undetectable HIV RNA on a multi-pill regimen, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IAS 2017: PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey

An estimated 120,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of retail and mail-order pharmacies by Gilead Sciences, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

IAS 2017: Another HIV Vaccine Efficacy Trial Will Start This Year

A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, now running, is only the eighth human vaccine efficacy trial ever run in the history of the HIV epidemic, and the first since 2009.

alt

Read more:

IAS 2017: Trans Women Wary of Antiretroviral Drug and Hormone Interactions

Transgender women with HIV may be hesitant to use antiretroviral therapy (ART) or not take it as prescribed because of concerns about drug interactions with feminizing hormones, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.alt

Read more:

IAS 2017: WHO Recommends Urgent Care Package for People with Advanced HIV Disease

A new package of measures to ensure rapid initiation of antiretroviral treatment and diagnosis of opportunistic infections has been recommended by the World Health Organization (WHO) to reduce the still high rates of death among people diagnosed with HIV at a very advanced stage of disease.

alt

Read more:

IAS 2017: Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks

Doctors need to monitor patients regularly for kidney function if they are taking tenofovir disoproxil fumarate (TDF), especially if combined with ritonavir, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IAS 2017: Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives

Urgent action is needed to improve access to the antifungal drug flucytosine, say investigators, following the presentation of the results of a trial showing that treatment containing flucytosine is superior to any other form of therapy in reducing the risk of death from cryptococcal meningitis in people with very advanced HIV disease.

alt

Read more: